Allergy Therapeutics PLC
LSE:AGY
Allergy Therapeutics PLC
Cash from Operating Activities
Allergy Therapeutics PLC
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Allergy Therapeutics PLC
LSE:AGY
|
Cash from Operating Activities
-£32.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-81%
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cash from Operating Activities
£6.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
AstraZeneca PLC
LSE:AZN
|
Cash from Operating Activities
$10.3B
|
CAGR 3-Years
29%
|
CAGR 5-Years
32%
|
CAGR 10-Years
3%
|
|
Indivior PLC
LSE:INDV
|
Cash from Operating Activities
-$315m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cash from Operating Activities
$608m
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cash from Operating Activities
£63.6m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
See Also
What is Allergy Therapeutics PLC's Cash from Operating Activities?
Cash from Operating Activities
-32.2m
GBP
Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Cash from Operating Activities amounts to -32.2m GBP.
What is Allergy Therapeutics PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-81%
Over the last year, the Cash from Operating Activities growth was -28%.